Patent 10464952 was granted and assigned to Venatorx Pharmaceuticals Inc. on November, 2019 by the United States Patent and Trademark Office.
Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.